The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 33798439.
- Also identified by DOI 10.1016/j.cell.2021.02.055 and PMC identifier 8459793.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
When it comes to precision oncology, proteogenomics may provide better prospects to the clinical characterization of tumors, help make a more accurate diagnosis of cancer, and improve treatment for patients with cancer. This perspective describes the significant contributions of The Cancer Genome Atlas and the Clinical Proteomic Tumor Analysis Consortium to precision oncology and makes the case that proteogenomics needs to be fully integrated into clinical trials and patient care in order for precision oncology to deliver the right cancer treatment to the right patient at the right dose and at the right time.
Medical subject headings
- Neoplasms
- Proteogenomics